Freeline (FRLN) Acquired by Syncona for $6.50/sh streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shares of Freeline Therapeutics Holdings plc (FRLN) are gaining over 10% on Wednesday morning after the company reported positive initial clinical data from first cohort of phase 1/2 trial of FLT201, its novel gene therapy candidate in Gaucher disease.
Freeline Therapeutics Holdings (FRLN) Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call Transcript August 15, 2023 Freeline Therapeutics Holdings plc misses on earnings expectations. Reported EPS is $-4.16 EPS, expectations were $3.62. Operator: Good morning, everyone, and welcome to the Freeline Second Quarter 2023 Financial and Business Update Conference Call. All participants will be in a listen-only mode. […]